Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Lymphoma 68Lymphoma, Non-Hodgkin 53Lymphoma, Large B-Cell, Diffuse 47Hodgkin Disease 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 41Small Cell Lung Carcinoma 37Leukemia 37Burkitt Lymphoma 32Lymphoma, Mantle-Cell 29Lymphoma, Follicular 28Lung Neoplasms 20Carcinoma, Non-Small-Cell Lung 20Multiple Myeloma 19Congenital Abnormalities 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, Large-Cell, Anaplastic 17Recurrence 15Lymphoma, B-Cell, Marginal Zone 15Lymphoma, B-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Neuroblastoma 13Neoplasms 13Myelodysplastic Syndromes 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, T-Cell 10Immunoblastic Lymphadenopathy 10Sarcoma 9Myeloproliferative Disorders 9

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × Etoposide × Clear all
NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
37 enrolled 25 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡